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Abstract Myostatin, a TGF-L family member, is a negative
regulator of muscle growth. Here, we generated transgenic mice
that expressed myostatin mutated at its cleavage site under the
control of a muscle specific promoter creating a dominant
negative myostatin. These mice exhibited a significant (20^35%)
increase in muscle mass that resulted from myofiber hypertrophy
and not from myofiber hyperplasia. We also evaluated the role of
myostatin in muscle degenerative states, such as muscular
dystrophy, and found significant downregulation of myostatin.
Thus, further inhibition of myostatin may permit increased
muscle growth in muscle degenerative disorders.
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1. Introduction
Skeletal muscle development and regeneration are regulated
positively by a variety of growth and transcription factors that
a¡ect both muscle stem cell proliferation and myotube di¡er-
entiation [1^3]. In particular, growth factors such as FGFs,
IGFs and TGF-Ls play a critical role in promoting myogen-
esis [4^9]. More recently, a negative regulator of skeletal
muscle growth, myostatin, was described [10^12]. Myostatin,
also known as growth di¡erentiation factor 8 (GDF-8) is a
member of the TGF-L superfamily [10^12]. Mice completely
lacking myostatin showed a profound increase in skeletal
muscle growth with both an increase in myo¢ber size and
an increase in myo¢ber number [11]. Thus, myostatin function
was implicated in both hypertrophy and hyperplasia of
muscle.
TGF-L family members undergo dimerization and cleavage
in the extracellular milieu to release the mature, active form
derived from the carboxyl-terminus [13,14]. We generated
transgenic mice expressing myostatin lacking its normal cleav-
age site. We predicted that this mutant would function in a
dominant negative manner since this approach has been suc-
cessful for the study of other TGF-Ls [15]. Mice expressing
this mutant myostatin exhibited an increase in skeletal muscle
mass as a result of widespread muscle hypertrophy. No in-
crease in hyperplasia was noted in mice expressing dominant
negative myostatin (dnMS) suggesting that the hypertrophic
e¡ect of myostatin was independent of its hyperplastic e¡ect.
Interestingly, muscle hypertrophy was independent of known
transcription factors that have previously been implicated in
muscle hypertrophy, including myogenin, GATA-2 and MEF-
2C. Since positive regulators of muscle growth have been
shown to be upregulated in muscle undergoing extensive re-
generation after damage [16,17], we predicted that a negative
regulator of muscle growth would be downregulated to atten-
uate its suppressive e¡ect and allow regeneration to proceed.
Consistent with this, we found myostatin transcript level de-
creased in two models of muscular dystrophy in which a sig-
ni¢cant degree of regeneration takes place after repetitive
cycles of degeneration [18,19]. Therefore, myostatin is a neg-
ative regulator of muscle hypertrophy, and its normal func-
tion can be inhibited through a dominant negative mecha-
nism.
2. Materials and methods
2.1. Generation of dnMS transgenic mice
The 5P and 3P ends of murine myostatin were ampli¢ed separately
with the following: (1)M5F 5P-TGGCGGCCGCCACCATGATG-
CAAAAACTG-3P, and M5R 5P-GTCTCCGTCTAGACCCTTGG-
GTGTGTCTGT-3P ; (2)M3F 5P-AAGGGTCTAGACGGAGACTT-
TGGGCTTGAC-3P, and M3R 5P-GAGTCGACTATAGATCCTC-
TTCGCTGATCAGCTTCTGCTCTGAGCACCCACAGCGGTCT-
A-3P. The PCR products were digested with XbaI and ligated to SmaI-
digested Bluescript II (KS), (Stratagene, LaJolla, CA, USA). The
normal cleavage site, amino acid sequence RSRR, was altered to
GLDG, and a c-myc epitope sequence was included in M3R. Poly-
adenylation and termination signals from the bovine growth hormone
gene were added. The 6.5 kb MCK promoter was inserted into a XhoI
site upstream of dnMS [20,21]. Sequences were veri¢ed using cycle
sequencing. The prokaryotic vector sequences were removed and the
DNA was puri¢ed as described [22]. Transgenic mice were generated
by microinjection into the pronucleus of fertilized single cell CD1
embryos as described [23]. The transgene copy number was estimated
in founder mice by Southern blot analysis of tail DNA with an K-32P
labeled DNA probe containing the ¢rst 810 bp of the myostatin cod-
ing sequence (nucleotides 107^817 of GenBank accession number
U84005). This probe detected both the dnMS transgene and the en-
dogenous myostatin gene.
2.2. Northern blot analysis
dnMS mRNA expression was detected with the same probe used
for Southern blotting. To detect endogenous myostatin and GDF-11
mRNA expression, 3P UTR sequences were used. For myostatin, nu-
cleotides 1387^1883 of GenBank accession number U84005 were used
as a probe. For GDF-11, nucleotides 1183^1584 of GenBank acces-
sion number AF092734 were used. Probes used to detected mRNA
expression of myogenin, GATA-2 and MEF-2C correlated to the
following regions: for myogenin, nucleotides 757^1229 of GenBank
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accession number X15784; for GATA-2, nucleotides 1981^2620 of
GenBank accession number NM_008090; and for MEF-2C, nucleo-
tides 520^1160 of GenBank accession number L13171. Probe sequen-
ces were all generated by RT-PCR and veri¢ed with direct sequencing
of PCR fragments. Signal strength was quanti¢ed using ImageQuant
software and a STORM 860 phosphorimager (Amersham-Pharmacia
Biotech, Piscataway, NJ, USA).
2.3. Immunoblotting, histology and immunocytochemistry
dnMS protein was detected with a polyclonal anti-c-myc antibody
(Upstate Biotechnology, Lake placid, NY, USA). Myostatin and
dnMS were detected with an antibody speci¢c to myostatin that rec-
ognizes both the precursor and amino-terminal processed form of
myostatin [24]. Goat anti-rabbit secondary was from Jackson Immu-
noResearch (West Grove, PA, USA), and signal strength was quanti-
¢ed using ECL Plus and a STORM 860 (Amersham-Pharmacia Bio-
tech). Coomassie blue stained gels were quanti¢ed using Kodak ID
2.0.2 (Eastman-Kodak, Rochester, NY, USA). Quadriceps, gastrocne-
mius, triceps brachialis, extensor digitalis longus (EDL) and soleus
muscles from 16-week-old mice were isolated and weighed, blinded
to genotype. Immunostaining was performed as described [25]. Three
sections from the midportion of each muscle were stained with poly-
clonal anti-dystrophin AB6^10 [26] that was detected with Cy3-con-
jugated goat anti-rabbit antibody (Jackson ImmunoResearch Labora-
tories, West Grove, PA, USA). Counterstaining with 4,6-diamidino-2-
phenylindole (DAPI) was included in the mounting medium (Vector
Laboratories, Burlingame, CA, USA). Sections were photographed on
a Zeiss Axiophot epi£uorescence microscope. For sections stained
with hematoxylin/eosin or Masson trichrome, the images were ac-
quired on a Kodak digital science DC 120 zoom digital camera and
analyzed using NIH Image.
3. Results
3.1. Expression of dnMS in transgenic mice
As shown in Fig. 1A, a dnMS was engineered by altering
the predicted cleavage site from RSRR to GLDG (residues
264^267 of GenBank accession number U84005). A c-myc
epitope tag, EQKLISEDDL, was added to the carboxyl-ter-
minus of the mutant myostatin. dnMS was expressed using a
6.5 kb fragment of the muscle-speci¢c creatine kinase (MCK)
promoter [20,21]. Four independent lines of transgenic mice
were generated on an outbred CD1 background. The trans-
gene copy number was 3, 15, 10 and 10 for lines 1, 2, 3 and 4,
respectively. Northern blot analysis demonstrated that dnMS
mRNA was expressed in all four transgenic lines (Fig. 1B,
upper panel) at the predicted size of 1.7 kb. The native myo-
statin transcript was 2.9 kb, and required longer exposure
times for visualization (data not shown). Despite varying
copy number, the amount of dnMS transcript was similar
from all four lines.
Immunoblotting of skeletal muscle extracts with anti-c-myc
antibody detected dnMS protein expression as the expected 50
kDa size in the transgenic mice (Fig. 1C). The relative level of
dnMS protein expression was about 113, 100, 136 and 169 for
lines 1, 2, 3 and 4, respectively (the lowest was considered as
100%). The 50 kDa band was consistent with the uncleaved
form of dnMS. No smaller bands were detected indicating
dnMS was resistant to cleavage. Because the MCK promoter
can express in both skeletal and cardiac muscle [21], we exam-
ined the expression of dnMS in cardiac muscle. Abundant
dnMS mRNA was detected in the hearts of all four transgenic
lines (data not shown). However, expression of dnMS protein
was not seen with the anti-c-myc antibody. Correspondingly,
the hearts from the dnMS mice were not hypertrophied.
To further investigate whether dnMS interfered with endog-
enous myostatin processing, we evaluated the amount of proc-
essed myostatin in both wild type and dnMS muscle. For
these experiments, we used an antibody directed at the ami-
no-terminus of myostatin. This antibody recognized both nor-
mal myostatin as well as mutant myostatin. The right panel of
Fig. 1D shows an absence of full length, uncleaved myostatin
(50 kDa) in the normal control consistent with fully cleaved
myostatin. In dnMS muscle, the processed form (37 kDa) was
reduced by 40% compared to normal muscle. The lanes were
Fig. 1. Expression of dnMS in transgenic mice. A: The cleavage site of myostatin was mutated from RSRR to GLDG to produce dnMS. The
hatchmarks indicate the positioning of disul¢de bridges that permit dimerization. B: Expression of dnMS mRNA (arrow) is shown in lanes 2,
3, 4 and 5 representing transgenic lines 1, 2, 3 and 4. Ribosomal RNA is shown on the lower panel as an RNA loading control. C: Immuno-
blot analysis of dnMS protein expression in skeletal muscle. The anti-c-myc antibody detects only the 50 kDa dnMS in transgenic lines 1, 2, 3
and 4, but not in normal muscle (N). The carboxyl-terminus of processed dnMS would be detected at 13 kDa, and is not present. Coomassie
blue staining (lower panel) shows an equal amount of protein loading. D: Immunoblot analysis of myostatin expression in dnMS and normal
skeletal muscle. Using an antibody that detects the amino-terminus of myostatin, a reduction of the processed form (37 kDa band) was consis-
tently present in dnMS muscle compared to normal control (N) (right panel). The reduction of processed myostatin ranged from 23 to 40%
and paralleled the increase in muscle mass. Coomassie blue staining was used to normalize protein content (left panel).
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equally loaded and normalized to the actin content (Fig. 1D,
left panel). Furthermore, the reduction in processed myostatin
was consistent among all four lines of dnMS transgenic mice
ranging from 23 to 40% consistent with the increase in muscle
mass (see below). Thus, dnMS had an inhibitory e¡ect on
endogenous myostatin processing.
3.2. Characterization of dnMS transgenic mice
All four lines of mice bearing the dnMS transgene appeared
Fig. 3. Analysis of dnMS mice. A: The cross sectional area of
muscle from dnMS transgenic mice was 20% larger than control lit-
termates. Cross sectional areas were determined from quadriceps
muscle taken at its midportion. n = 5 in each group. B: Myo¢ber
number per mm2 in cross sections from transgene bearing mice was
379 þ 76 versus 467 þ 31 in control littermates indicating that the
number of myo¢bers per section was less due to increased myo¢ber
size. C: The number of nuclei per myo¢ber remained similar be-
tween dnMS mice and their control littermates indicating no in-
crease in nuclear number and an absence of hyperplasia. Error
bar = S.D. The asterisk indicates the P value for dnMS mice versus
control littermates is 6 0.01.
Fig. 2. Characterization of mice expressing dnMS. A: A freshly de-
skinned hindlimb from a myostatin transgenic mouse (dnMS) shows
more pronounced musculature than a control, gender-matched litter-
mate (control). B: Individual muscle mass comparison in male mice.
The average muscle mass from male transgenic mice was 17, 35 and
23% greater than the control group for gastrocnemius, triceps and
quadriceps, respectively. In female mice (C), the increase was 16, 21
and 27.5% for gastrocnemius, triceps and quadriceps, respectively.
n = 10 for each muscle group; Error bar = S.E.M. The asterisk indi-




X. Zhu et al./FEBS Letters 474 (2000) 71^75 73
healthy and in the expected Mendelian ratio. Fig. 2A shows a
representative comparison of deskinned dnMS transgenic and
wild type littermate hind limbs. The transgenic mice fre-
quently had muscles that were visibly more developed than
their wild type littermates. The pronounced musculature was
consistently observed in dnMS transgenic mice of all four
lines and in both male and female dnMS transgenic mice.
As shown in Fig. 2B, the average muscle mass of male trans-
genic mice was increased 17, 35 and 23% for gastrocnemius,
triceps brachialis and quadriceps respectively over littermate
controls. Individual muscle mass from female transgenic mice
was also greater than littermates (16% for gastrocnemius, 21%
for triceps and 28% for quadriceps) (Fig. 2C).
To investigate whether the increase in skeletal muscle mass
in dnMS transgenic mice arose from hypertrophy and/or hy-
perplasia, we quanti¢ed muscle ¢ber size and myonuclear
number. Fig. 3A shows that the average cross sectional area
of dnMS quadraceps muscle was 20% larger than the control
muscle (15.33 þ 1.96 mm2 for transgenic and 12.33 þ 1.52
mm2) at its mid-portion. Fig. 3B demonstrates that dnMS
muscle averaged 379 þ 76 myo¢ber/mm2 while wild type litter-
mates averaged 467 þ 31 myo¢ber/mm2. In dnMS mice, the
smaller number of myo¢bers per given area re£ected an in-
crease in myo¢ber size indicating hypertrophy. Moreover, a
comparison of fast (EDL) and slow (soleus) muscle cross sec-
tional areas indicated that hypertrophy occurred in both
muscle types (Table 1). As a measure of hyperplasia, the
number of nuclei per myo¢ber was calculated. Both wild
type and dnMS mice showed the same number of nuclei per
myo¢ber (Fig. 3C, 1.31 þ 0.15 for wild type and 1.28 þ 0.06 for
dnMS) in each section indicating that hyperplasia was not a
signi¢cant contributor to the increase in muscle size seen in
dnMS transgenic mice.
We examined whether hypertrophy in dnMS muscle relied
on the upregulation of transcription factors previously impli-
cated in muscle hypertrophy [6^9,27]. Quantitative Northern
blot analysis was performed on total RNA from normal and
mutant gastrocnemius muscle (n = 9 for each). No signi¢cant
di¡erence was detected in the expression of MEF-2C, myoge-
nin or GATA-2 (Fig. 4A). Thus, dnMS-mediated hypertrophy
occurred by mechanisms that did not involve an increase in
these transcription factors.
3.3. Myostatin was downregulated in regenerating muscle from
muscular dystrophy mice
To examine whether myostatin expression was altered in
skeletal muscle undergoing regeneration, mice with muscular
dystrophy were examined. mdx mice lack dystrophin and are a
model for Duchenne muscular dystrophy [28] while gsg3=3
mice lack Q-sarcoglycan and serve as a model for limb girdle
muscular dystrophy [29]. These animal models exhibit re-
peated and continuous rounds of degeneration accompanied
by regeneration [29,30]. Eight-week, gender-matched mice of
each strain, mdx, gsg3=3 and wild type, were studied. As
shown in Fig. 4B, myostatin mRNA expression was signi¢-
cantly reduced in mdx and gsg3=3 mice (upper panel), while
GDF-11, a homolog of myostatin was not a¡ected (middle
panel).
4. Discussion
We found that mice expressing dnMS showed up to a 35%
increase in skeletal muscle mass, and this increase was a result
of muscle hypertrophy. Interestingly, hypertrophy equally af-
fected slow and fast ¢bers. Notably, hyperplasia was not a
signi¢cant contributor to the increase in muscle mass. In com-
parison to dnMS mice, mice fully null for myostatin showed
muscle masses that were nearly double that of normal muscle
[11]. In addition, this marked increase in muscle mass was
associated with both hypertrophy and hyperplasia [11]. The
di¡erence in muscle mass seen in dnMS and null myostatin
mice likely results from incomplete dominance of dnMS so
Table 1
Comparison of fast (EDL) and slow (soleus) muscle cross sectional
area
Cell number per mm2
wild type dnMS
EDL 549 þ 32 430 þ 92a
soleus 546 þ 32 432 þ 36a
n = 5 for each muscle group.
aIndicates P value for dnMS versus wild type is 6 0.01.
Fig. 4. A: mRNA expression of MEF2C, myogenin and GATA-2
in muscles from normal (3) and dnMS transgenic (+) mice. The re-
sults from two di¡erent mice in each group are shown. The same
blot was also hybridized with L-actin probe and used for normaliza-
tion. B: Myostatin mRNA expression in muscle from normal mice
and mice with muscular dystrophy. Myostatin mRNA expression
was signi¢cantly decreased in gsg3=3 and mdx mice (top panel).
GDF-11, a homolog of myostatin, was not a¡ected (middle panel).
The same blot was also hybridized with L-actin probe for normal-
ization (bottom panel).
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that dimerization and cleavage of normal myostatin is not
fully blocked in dnMS mice. Expression from the dnMS trans-
gene produced a 23^40% decrease in processed myostatin, and
this degree of reduction paralleled the increase in muscle mass.
Thus, lower levels of myostatin inhibition may a¡ect hyper-
trophy, while higher levels of myostatin inhibition may be
required to alter hyperplasia. We cannot exclude that dnMS
may interfere with other closely related TGF-Ls whose normal
function is to promote muscle growth. Additionally, the MCK
promoter that directed expression of dnMS may express later
in development, beyond the developmental window in which
skeletal muscle cell proliferation is complete. Supporting this,
the muscle creatine kinase gene was noted to be highly ex-
pressed in fetal but not embryonic myotubes [31]. Neverthe-
less, it appears that dnMS e¡ectively separates the regulation
of myo¢ber size from the regulation of myo¢ber number in a
manner distinct from that seen in myostatin null mice.
The double muscled phenotype has arisen in several di¡erent
strains of cattle and is associated with at least two di¡erent
myostatin mutations. One mutation resulted in a truncated
myostatin protein similar to the dnMS we engineered here
[10,32]. This breed displayed a 20^25% increase in muscle
mass, similar to that observed in dnMS mice [10]. A second
mutation was also associated with the double muscled pheno-
type in cattle, resulting in a missense mutation in the active
portion of myostatin [10]. The increase in muscle mass asso-
ciated with this breed is also 20^25%. Based on our observa-
tions, it is likely that these mutants exhibit their e¡ect in a
dominant negative manner.
It is not known what transcription factors might mediate
the hypertrophic e¡ect of dnMS. We tested three transcription
factors, MEF-2C, myogenin and GATA-2, whose functions
have been previously well established in muscle hypertrophy.
The observation that these three transcription factors were
not increased in hypertrophic muscle from dnMS transgenic
mice indicates that alternative signaling pathways and/or oth-
er transcription factors mediate myostatin-inhibited hypertro-
phy. We also found myostatin expression was signi¢cantly
reduced in two strains of mice that undergo muscle degener-
ation coupled with extensive regeneration. Skeletal muscle de-
velopment and regeneration are highly paralleled processes
under balanced regulation. Myostatin is well positioned as a
negative regulator of these processes. Inhibiting myostatin
may be a useful tool in the treatment of muscle degenerative
diseases such as the muscular dystrophies or aging-associated
muscle degeneration. The identi¢cation and demonstration of
a dominant negative form of myostatin o¡ers a more facile
molecular mechanism to interfere with myostatin function in
diseased tissues.
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